Feb 13, 2017

Why Marathon's defense of its drug price hike falls short

Chris Potter / Flickr Creative Commons

John Carroll at the pharmaceutical news website Endpoints did some interesting digging on the new high-priced drug from Marathon Pharmaceuticals for Duchenne muscular dystrophy. The drug company claims that the annual $89,000 list price is justified to recoup the lofty research and development costs and that it won't be profitable for years, but Carroll found that defense probably doesn't hold up. The key points:

  • Carroll consulted with two pharmaceutical industry experts, who analyzed the data and said the costs for acquiring and developing the drug were as low as $6 million and likely no more than $75 million.
  • A slide from a webinar about the effort listed no new registrational studies, which are usually the most expensive part of research and development costs.
  • Assuming Marathon only gets the negotiated rate of $54,000, the company would only have to treat 200 to 1,400 U.S. patients who have Duchenne (or no more than 8% of the market) in one year "to cover a barebones R&D effort." And don't forget: Marathon has seven years of exclusive monopoly pricing for the drug, and it acquired a valuable "priority review voucher" that can be sold or used to speed along a new drug.

Go deeper

Coronavirus updates: U.S. probes case with no clear links, virus hits more countries

Data: The Center for Systems Science and Engineering at Johns Hopkins, the CDC, and China's Health Ministry. Note: China numbers are for the mainland only and U.S. numbers include repatriated citizens.

The CDC said Wednesday U.S. clinicians have found the novel coronavirus in a person who did not recently return from a foreign country nor knowingly have contact with anyone infected, as six more countries reported their first cases.

The big picture: COVID-19 has killed more than 2,800 people and infected over 82,000 others. The number of new cases reported outside China exceeded those inside the country for the first time on Tuesday, the WHO said Wednesday. South Korea has the most, with 1,595 infections confirmed by Wednesday night. Europe's biggest outbreak is in Italy, where 453 cases have been confirmed.

Go deeperArrowUpdated 3 mins ago - Health

WHO health official leads criticism of Trump's coronavirus response

President Trump with members of the new coronavirus task force, including Vice President Mike Pence at the White House on Wednesday. Photo: Tasos Katopodis/Getty Images

Dr. Ezekiel Emanuel, special advisor to the director general of the World Health Organization, told MSNBC Wednesday he found "most" of what President Trump said at his briefing on the novel coronavirus "incoherent."

The big picture: As the number of confirmed cases reaches 60 in the U.S., the top health professional — who was a health policy adviser in the Obama administration — is among several leading figures, in particular, Democrats, to criticize the president for his response to the outbreak.

Go deeperArrow31 mins ago - Health

Trump assigns Pence to lead U.S. coronavirus response


President Trump announced at a press briefing Wednesday evening that he'll be putting Vice President Mike Pence in charge of leading the administration's response to the coronavirus.

The big picture: In the wake of a market sell-off and warnings from health officials that there's a real threat of the coronavirus spreading in the U.S., Trump sought to reassure the nation and Wall Street that the U.S. is "ready" for whatever comes next.

Go deeperArrowUpdated 3 hours ago - Politics & Policy